Pharmosa Biopharm Inc. (TPEX:6875)

Taiwan · Delayed Price · Currency is TWD

37.25

-0.70 (-1.84%)

At close: Jul 9, 2026

-6.99% (1Y)

Market Cap	4.90B -15.2%
Revenue (ttm)	69.06M -58.8%
Net Income	-385.09M
EPS	-2.98
Shares Out	129.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,401
Open	38.30
Previous Close	37.95
Day's Range	36.85 - 38.40
52-Week Range	33.60 - 65.00
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharm... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 40

Stock Exchange Taipei Exchange

Ticker Symbol 6875

Full Company Profile

Financial Performance

In 2025, Pharmosa Biopharm's revenue was 67.27 million, a decrease of -59.86% compared to the previous year's 167.57 million. Losses were -383.85 million, 130.3% more than in 2024.

Financial Statements